Previous close | 14.66 |
Open | 14.86 |
Bid | 14.92 x N/A |
Ask | 15.06 x N/A |
Day's range | 14.86 - 14.86 |
52-week range | 7.58 - 15.16 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Elanco Animal Health Inc (NYSE:ELAN), a company specializing in the development, manufacturing, and marketing of products for animal health and production, has reported an insider purchase filed with the SEC.
Elanco Animal Health (NYSE: ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary. O'Neill will be responsible for the global strategy and operations of the Company's legal team, ethics & compliance organization and ESG efforts.
Investment firm Ancora Holdings said it is pushing for four board seats at Elanco Animal Health and wants to replace the chief executive at the company that makes medicines and vaccinations for pets and livestock. Ancora nominated the director candidates, including one of the firm's executives, to Elanco's 12-person board and wants to oust CEO Jeffrey Simmons over what the activist investor calls poor performance. Elanco, which was spun out of pharmaceutical company Eli Lilly, is one of the world's leading developers and makers of animal health products and has a market value of $7.8 billion.